ArticleFrontiers in endocrinology2025
Normal adrenocorticotropic hormone levels do not exclude adrenal insufficiency during immune checkpoint inhibitor therapy: evidence from clinical, steroid, and structural analyses.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune checkpoint inhibitor-related endocrinopathies: from immune crosstalk to predictive biomarkers and precision management.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone (ACTH) deficiency (ICI-IAD) represents a critical endocrine immune-related adverse event (irAE) that may become life-threatening without timely diagnosis. Most cases present with suppressed ACTH and cortisol levels; however, a subset of patients shows preserved ACTH levels despite biochemical evidence of adrenal insufficiency. The mechanism and clinical implications underlying this discordance remain poorly defined. This study aimed to investigate the pathophysiological basis and clinical significance of preserved ACTH in patients with ICI-IAD. Methods: This study involved retrospective and prospective analysis of 49 patients diagnosed with ICI-IAD. Based on plasma ACTH levels, patients were categorized into ACTH-preserved (≥10 pg/mL) and ACTH-depleted (<10 pg/mL) groups. Comparisons included clinical characteristics, hormone responses to stimulation tests, steroid metabolite levels, and molecular features of circulating ACTH. Results: The ACTH-preserved phenotype accounted for 14% of the cohort. Clinical characteristics-including cancer types and ICI regimens-did not differ significantly between the two groups. Despite preserved ACTH levels, cortisol and downstream steroid production remained equally suppressed. All patients who underwent the Synacthen test showed impaired adrenal reserve, confirming that adrenal insufficiency occurred even in cases with preserved-range ACTH values. Corticotropin-releasing hormone stimulation tests revealed similarly blunted pituitary responses in both groups. Gel filtration chromatography identified high-molecular-weight ACTH forms in the preserved group, suggesting altered proopiomelanocortin processing or post-translational modifications that impaired ACTH bioactivity. Conclusions: Adrenal insufficiency may occur when plasma ACTH levels remain within or above the normal range. Diagnosis based solely on ACTH measurements risks underrecognition of ICI-IAD. Comprehensive endocrine assessment-including dynamic hormone testing and detailed steroid profiling-enhances diagnostic accuracy and informs timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.